Celltrion Partners To Form New Biosimilars JV in ChinaBy
Celltrion, an Incheon, Korea-based biopharmaceutical company developing innovator drugs and biosimilars, and Nan Fung Group, a Hong Kong-based conglomerate, have formed a joint-venture company, Vcell Healthcare, to develop biosimilars in China. Vcell has simultaneously signed a licensing agreement with Celltrion for three biosimilar products.
Vcell Healthcare will obtain exclusive rights in mainland China to develop, manufacture and commercialize three biosimilars from Celltrion: Remsima (infliximab), a biosimilar of Johnson & Johnson’s Remicade; Truxima (rituximab), a biosimilar of Roche’s/Biogen’s Rituxan; and Herzuma (trastuzumab), a biosimilar of Roche’s Herceptin.
Vcell Healthcare says it aims to launch these products in China following regulatory approval. In the meantime, Celltrion and Nan Fung Group will collectively explore the opportunity to develop a biologics manufacturing facility in China.
Source: Vcell Healthcare Limited